246 related articles for article (PubMed ID: 34168446)
1. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice.
Chu Q; Mu W; Lan C; Liu Y; Gao T; Guan L; Fang Y; Zhang Z; Liu Y; Liu Y; Zhang N
Int J Nanomedicine; 2021; 16():4161-4173. PubMed ID: 34168446
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.
Yi B; Wu T; Zhu N; Huang Y; Yang X; Yuan L; Wu Y; Liang X; Jiang X
J Nanobiotechnology; 2021 Mar; 19(1):74. PubMed ID: 33726759
[TBL] [Abstract][Full Text] [Related]
3. A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma.
Huang XY; Li F; Li TT; Zhang JT; Shi XJ; Huang XY; Zhou J; Tang ZY; Huang ZL
J Nanobiotechnology; 2023 Jan; 21(1):25. PubMed ID: 36681851
[TBL] [Abstract][Full Text] [Related]
4. Biofunctionalized magnetic nanospheres-based cell sorting strategy for efficient isolation, detection and subtype analyses of heterogeneous circulating hepatocellular carcinoma cells.
Chen L; Wu LL; Zhang ZL; Hu J; Tang M; Qi CB; Li N; Pang DW
Biosens Bioelectron; 2016 Nov; 85():633-640. PubMed ID: 27240010
[TBL] [Abstract][Full Text] [Related]
5. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
[TBL] [Abstract][Full Text] [Related]
6. Circulating biomarkers in hepatocellular carcinoma.
Morris KL; Tugwood JD; Khoja L; Lancashire M; Sloane R; Burt D; Shenjere P; Zhou C; Hodgson C; Ohtomo T; Katoh A; Ishiguro T; Valle JW; Dive C
Cancer Chemother Pharmacol; 2014 Aug; 74(2):323-32. PubMed ID: 24923562
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma.
Takahashi K; Ofuji K; Hiramatsu K; Nosaka T; Naito T; Matsuda H; Endo K; Higuchi M; Ohtani M; Nemoto T; Nakamoto Y
Cancer Med; 2021 Apr; 10(7):2300-2309. PubMed ID: 33675149
[TBL] [Abstract][Full Text] [Related]
9. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
10. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
12. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry.
Mu H; Lin KX; Zhao H; Xing S; Li C; Liu F; Lu HZ; Zhang Z; Sun YL; Yan XY; Cai JQ; Zhao XH
World J Gastroenterol; 2014 May; 20(19):5826-38. PubMed ID: 24914343
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.
Hagag NA; Ali YBM; Elsharawy AA; Talaat RM
J Gastrointest Cancer; 2020 Mar; 51(1):234-241. PubMed ID: 31028536
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
15. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
[TBL] [Abstract][Full Text] [Related]
16. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
17. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study.
Hamaoka M; Kobayashi T; Tanaka Y; Mashima H; Ohdan H
PLoS One; 2019; 14(5):e0217586. PubMed ID: 31141571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
